Drug Type Bispecific killer cell engager (BiKE) |
Synonyms |
Target |
Action modulators |
Mechanism CD16a modulators(Low affinity immunoglobulin gamma Fc region receptor III-A modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | United States | 13 Sep 2021 | |
Hematologic Neoplasms | Preclinical | United States | 29 Mar 2022 | |
Solid tumor | Preclinical | United States | 29 Mar 2022 |